Overview
Optic nerve hypoplasia (ONH) is a congenital anomaly characterized by underdevelopment of the optic nerve, often leading to visual impairment. It frequently occurs as part of a broader syndrome involving midline brain malformations and endocrine dysfunction, rather than in isolation 3.Diagnosis
Clinical Presentation: Vision impairment, nystagmus, and ocular deviations (exotropia, esotropia) 5.
Imaging: MRI or CT to identify optic nerve hypoplasia, corpus callosum hypoplasia, and other brain malformations 25.
Endocrine Evaluation: Testing for hypopituitarism, including thyroid function, growth hormone, and cortisol levels 25.
Developmental Assessment: Use standardized tools like the Battelle Developmental Inventory to evaluate developmental milestones 2.Management
Early Intervention: Multidisciplinary approach including physical, occupational, and developmental therapies 3.
Endocrine Support: Hormone replacement therapy tailored to specific deficiencies (e.g., growth hormone, thyroid hormone, cortisol) 25.
Vision Therapy: Specialized ophthalmic interventions to manage visual impairment and nystagmus 2.Special Populations
Pediatrics: High prevalence of developmental delay, especially in bilateral cases; frequent association with hypothalamic dysfunction and hypopituitarism 23.
Pregnancy: Potential teratogenic effects of certain medications; monitor for associations with ONH and septo-optic dysplasia 1.Key Recommendations
Comprehensive Evaluation: Conduct thorough neuroradiographic, endocrinologic, and developmental assessments in children with ONH to identify associated pathologies (Evidence: Moderate 2).
Early Intervention Programs: Implement early intervention services to address developmental delays observed in pediatric patients with ONH (Evidence: Moderate 3).
Endocrine Monitoring and Therapy: Regularly screen for and treat hypopituitarism with appropriate hormone replacement therapy (Evidence: Moderate 25).
Teratogen Awareness: Pregnant women should be counseled on potential teratogenic risks associated with certain medications that may lead to ONH (Evidence: Weak 1).References
1 Ali A, Azhari JO, Gise R, Solyman O, Phillips PH, Elhusseiny AM. Investigating drug-induced optic nerve hypoplasia and septo-optic dysplasia from the FDA adverse events database. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie 2025. link
2 Garcia-Filion P, Epport K, Nelson M, Azen C, Geffner ME, Fink C et al.. Neuroradiographic, endocrinologic, and ophthalmic correlates of adverse developmental outcomes in children with optic nerve hypoplasia: a prospective study. Pediatrics 2008. link
3 Borchert M, Garcia-Filion P. The syndrome of optic nerve hypoplasia. Current neurology and neuroscience reports 2008. link
4 Katz B, Wiley CA, Lee VW. Optic nerve hypoplasia and the syndrome of nevus sebaceous of Jadassohn. A new association. Ophthalmology 1987. link33244-0)
5 Krause-Brucker W, Gardner DW. Optic nerve hypoplasia associated with absent septum pellucidum and hypopituitarism. American journal of ophthalmology 1980. link90237-8)